Evaluation of In Vivo Probiotic Efficiency of Bacillus amyloliquefaciens in Labeo rohita Challenged by Pathogenic Strain of Aeromonas hydrophila MTCC 1739.Probiotics Antimicrob Proteins. 2018 06; 10(2):391-398.PA
Diseases in aquatic organisms, including fish, are a major concern in aquaculture production. In this present investigation, we have evaluated the beneficial effects of dietary Bacillus amyloliquefaciens CCF7 (GenBank Acc. No. KP256501) supplementation in rohu (Labeo rohita) challenged by a pathogenic strain of Aeromonas hydrophila MTCC 1739. Four experimental diets were formulated: control diet (no probiotics) and three experimental diets (different concentrations of probiotic candidate B. amyloliquefaciens CCF7 at 105 (T1), 107 (T2), 109 (T3) CFU/g). Further, we have divided the feeding trial into pre-challenge (70 days) and post-challenge (28 days) periods and various immune parameters (serum protein, globulin, albumin, lysozyme, and IgM), and stress parameters (malondialdehyde, catalase, and superoxide dismutase) were examined during both the periods. Throughout the entire experiment, control group was fed with probiotic free basal diet, while the treatment groups received probiotic supplemented diets (PSD). After challenge test, serum aspartate transaminase (AST), serum alanine transaminase (ALT) activity, and liver malondialdehyde level have increased significantly in control groups; however, level of these parameters were considerably lower in fish fed with PSD. In contrast, liver catalase and superoxide dismutase activities and serum globulin concentration was significantly higher in the group fed with T3 diet followed by T2. Furthermore, an elevated level of serum IgM and higher activity of serum lysozyme was also recorded in PSD fed groups, especially for T3 group which confirmed the probiotic efficiency of the bacterium B. amyloliquefaciens CCF7. We strongly believe that B. amyloliquefaciens CCF7 will be a good probiotic candidate in aquaculture industries.